Nova proposta de modelo murino de asma aguda: utilização de protocolo curto sem adjuvante com sensibilização a ovalbumina

• Ano de defesa: 2011
• Autor(a) principal: Rodrigues, Andréa Mendonça
• Orientador(a): Pitrez, Paulo Márcio Condessa
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Pontifícia Universidade Católica do Rio Grande do Sul; Porto Alegre
• Palavras-chave em Português: MEDICINA; ASMA; EPIDEMIOLOGIA EXPERIMENTAL; PROTOCOLOS CLÍNICOS; MEDICAMENTOS
• Link de acesso: http://hdl.handle.net/10923/4722

Introduction: Some limitations have been raised over the murine models with ovalbumin (OVA) sensitization in asthma research. However, this model is still widely used and the acute OVA protocol in mice still plays a role in pre-clinical investigation. The use of adjuvant and long sensitization periods are some of the limitations raised. Aims: We have tested whether a shorter period of subcutaneous sensitization with OVA, with no adjuvant, induces a similar eosinophilic pulmonary response in mice, when compared with previous well-established control protocols. Methods: Adult female BALB/c mice were used and divided into groups, according to the number of OVA sensitizations (once or twice, OVA: 20 μg) and the number (two or three times) /dosage(40 μg and 100 μg) of intranasal OVA challenge. The shorter protocol (10 days-length) consisted of one subcutaneous OVA sensitization and three OVA challenges (100 μg). Total (TCC) and differential cell counts from bronchoalveolar lavage (BAL), eosinophil peroxidase (EPO) from lung tissue and histopathology (HE) of the lungs were performed 24 hours after the last OVA challenge. Results: Cell counts from BAL, EPO from lung tissue and histological lung abnormalities were not different between the groups studied. The shorter protocol induced a similar allergic lung response to OVA, when compared with the positive control, the same occurring with the other groups. Conclusion: We concluded that the use of one subcutaneous OVA sensitization elicit a strong allergic pulmonary response, free of adjuvant, in a 10-day-length protocol. Our findings suggest that this protocol may be used a first-line pre-clinical test, reducing cost and time of experiments, and avoiding the use of artificial adjuvants.